Hints and tips:
Related Special Reports
...It has also worked on drug development for US pharma company Johnson & Johnson, Danish biotech group Genmab and British biotech Iksuda therapeutics....
...Pointing to increases in AstraZeneca’s research and development budget under Soriot, the successful launch of many blockbuster drugs and the expansion of the business into rare diseases, vaccines and immunology...
...In the past year, Novo Nordisk has become Europe’s largest company by market capitalisation, while Eli Lilly overtook Johnson & Johnson as the world’s most valuable pharma company, on the back of high demand...
...Others soon followed, such as PAVE, the Global X US Infrastructure Development ETF, and ROBO, the Global Robotics and Automation Index ETF. “A good ticker can go a long way in attracting investors....
...Todd Rosenbluth, head of research at VettaFi, a consultancy, also believed the growth of model portfolios was a positive development....
...Concentration “is as high as it has been, certainly for the past three decades, potentially even longer”, said Dimitris Melas, head of index research and product development at MSCI....
...High demand for weight-loss drugs has helped Novo Nordisk become Europe’s largest company by market capitalisation, while Eli Lilly overtook Johnson & Johnson as the world’s largest pharmaceutical company...
...Spravato, a nasal spray based on a molecule from the psychedelic drug ketamine used to treat depression, already ranks as Johnson & Johnson’s fastest-growing product....
...Psoriasis drugs were the first to turn dermatology into a high value market, with sales of Stelara by Johnson & Johnson exceeding $10bn a year; four other psoriasis treatments have annual sales above $2.5bn...
...“We are committed to GBTC and growing the ecosystem around it,” he said. “There is a lot of investor interest and excitement about the development of an options ecosystem.”...
...Some research has shown tirzepatide, the active ingredient in Mounjaro and Zepbound, has better efficacy. Zepbound is also cheaper than Wegovy....
...[MUSIC PLAYING] Hot Money is a production of the Financial Times and Pushkin Industries. It was written and reported by me, Miles Johnson....
...Johnson & Johnson joins the Merck, Bristol Myers Squibb and pharmaceutical lobby Pharmaceutical Research and Manufacturers of America in challenging the new law....
...The company joins Merck, Bristol Myers Squibb and the lobby group Pharmaceutical Research and Manufacturers of America in challenging the new law....
...Domestically, she points to a range of growth-boosting reforms, such as the rollout of the nationwide goods and services tax, which replaced a multitude of local taxes; as well as infrastructure development...
...The four pharmaceutical companies that part-funded the project — Amgen, AstraZeneca, GSK and Johnson & Johnson, — received nine months’ exclusive access to the data, which will now be made available to approved...
...The government unveiled plans earlier this year for £150mn of investment in the biobank, whose data has already been used by drugs companies including AstraZeneca and Johnson & Johnson....
...Zach Pandl, managing director of research for Grayscale, downplayed the rush out of the firm’s bitcoin ETF, which remains the largest by far....
...Todd Rosenbluth, head of research at VettaFi, said Goldman’s accelerator “taps into the company’s broader expertise and connections within the ETF industry....
...Shares in Sanofi fell 19 per cent on Friday after the French pharmaceutical group announced a lower profit outlook and a spinout of its consumer care unit as it seeks to focus on drug research....
...It has grabbed the top two places in the flows chart for the first nine months of the year via its US (JREU) and Global (JREG) Research Enhanced Equity (ESG) Ucits ETFs, as well as a further nine spots in...
...Other drugmakers including Merck, Bristol Myers Squibb, and Johnson & Johnson, as well as the US pharmaceutical lobby group, have already filed lawsuits against the reforms....
...He said Lilly had benefited from its strong research culture and breakthroughs in the two biggest untapped pharmaceutical markets....
...at the ETF Think Tank, the research division of Tidal Financial Group....
...Johnson & Johnson is fighting a bruising battle over tens of thousands of claims its talcum powder caused cancer....
International Edition